CliffBio
small molecule

ELIGLUSTAT TARTRATE

ELIGLUSTAT TARTRATE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameELIGLUSTAT TARTRATE
Active ingredientELIGLUSTAT TARTRATE
StrengthEQ 84MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2024
Marketing statusDISCN

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ELIGLUSTAT TARTRATE patent cliff — loss of exclusivity — | CliffBio